Immunotherapy with Autologous HIV-Loaded Dendritic Cells

使用携带 HIV 的自体树突状细胞进行免疫治疗

• 批准号: 8091773
• 负责人: CHARLES R RINALDO
• 金额: $ 3.33万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-02 至 2012-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8091773
• 关键词: Autologous; Dendritic Cells; Immunotherapy

Control of HIV-1 infection in chronically infected patients has been revolutionized by highly active antiretrovirai therapy (HAART). However, long term HAART is toxic and there is incomplete recovery of anti-HIV-1 T cell function; removal of HAART usually also results in rapid increases in viral load. Thus, we postulate that immunotherapy specifically directed to autologous virus can lead to adequate control of residual HIV-1 infection during HAART. We hypothesize that dendritic cells (DCs) loaded with apoptotic, autologous cells that are infected with autologous HIV-1 can serve as potent immunogens for activation of both CD8* and CD4 ¿ T cells specific for a broad range of autologous HIV-1 antigens. This is based on our recent findings that DCs loaded with HIV-1 infected, apoptotic cells induce CD8* and CD4* T cell responses specific for HIV-1 in vitro. To further refine this model, we propose to expand our preclinical studies by comparing the immunogenicity and the breadth of antigen specificity induced ex vivo by DCs loaded with apoptotic cells infected with autologous HIV-land DCs matured by different cytokine milieus. We will use this ex vivo model for determining the safety and immunogenicity of ex vivo loaded, autologous DCs as an HIV-1 immunogen in HIV-1 infected adults on HAART in a phase I clinical trial. Finally, we propose to monitor the breadth of CD8 ¿ and CD4 ¿ T cell responses to autologous HIV-1 and characterize viral evolutionary changes before and after ex vivo immunization. This DC-apoptotic cell model may be an ideal immunogen in that it contains all forms of HIV-1 proteins and can be used as a vehicle for therapeutic immunization with autologous virus.

在慢性感染患者中控制HIV-1感染已经发生了革命性的变化， 抗逆转录病毒疗法（HAART）。然而，长期的HAART是有毒的， 抗HIV-1 T细胞功能; HAART的去除通常也会导致病毒载量的快速增加。因此，在本发明中， 我们假设，针对自体病毒的特异性免疫治疗可以导致足够的控制， HAART期间残留的HIV-1感染。我们假设，负载有 被自体HIV-1感染的凋亡的自体细胞可以作为有效的免疫原 用于激活对广泛的自体HIV-1抗原具有特异性的CD 8 * 和CD 4 <$T细胞。 这是基于我们最近的发现，即负载HIV-1感染的凋亡细胞的DC诱导CD 8 + T细胞亚群的表达。 和体外对HIV-1特异的CD 4 * T细胞应答。为了进一步完善这一模式，我们建议 通过比较免疫原性和抗原特异性的广度来扩展我们的临床前研究 由负载有自体HIV感染的凋亡细胞的DC离体诱导，以及由 不同的细胞因子环境。我们将使用这种离体模型来确定安全性和免疫原性 体外负载的自体DC作为HIV-1免疫原在接受HAART的HIV-1感染成人中的作用 I期临床试验。最后，我们建议监测CD 8 <$T细胞和CD 4 <$T细胞反应的广度， 自体HIV-1和表征离体免疫之前和之后的病毒进化变化。 这种DC-凋亡细胞模型可能是一种理想的免疫原，因为它包含所有形式的HIV-1蛋白 并可用作自体病毒治疗性免疫的载体。